GlassScriptPhysician profile
Charles Denby, II
NPI 1669554481
$1,665.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $10.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $467.48 | 2019 | |
| Allergan, INC. | $332.97 | 2019 | |
| Shire North American Group INC | $167.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $132.09 | 2019 | |
| Ironshore Pharmaceuticals INC. | $112.26 | 2019 | |
| Sunovion Pharmaceuticals INC. | $102.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $87.08 | 2019 | |
| Neurocrine Biosciences, INC. | $73.88 | 2019 | |
| Lundbeck LLC | $63.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $61.81 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.53 | 2019 | |
| Neos Therapeutics, LP | $20.17 | 2019 | |
| Neuronetics, INC. | $19.10 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Denby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.